JP5592490B2 - シアノビリン−ｎ変異体、その修飾誘導体及びその応用 - Google Patents

シアノビリン−ｎ変異体、その修飾誘導体及びその応用 Download PDF

Info

Publication number
JP5592490B2
JP5592490B2 JP2012527184A JP2012527184A JP5592490B2 JP 5592490 B2 JP5592490 B2 JP 5592490B2 JP 2012527184 A JP2012527184 A JP 2012527184A JP 2012527184 A JP2012527184 A JP 2012527184A JP 5592490 B2 JP5592490 B2 JP 5592490B2
Authority
JP
Japan
Prior art keywords
lcvn
sequence
cyanovirin
mpeg
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012527184A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013503609A (ja
Inventor
シオン、シェン
チェン、ウェイ
クィアン、チュイウェン
ワン、イフェイ
海雄 北里
Original Assignee
ジナン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジナン ユニバーシティ filed Critical ジナン ユニバーシティ
Publication of JP2013503609A publication Critical patent/JP2013503609A/ja
Application granted granted Critical
Publication of JP5592490B2 publication Critical patent/JP5592490B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2012527184A 2009-09-04 2010-05-24 シアノビリン−ｎ変異体、その修飾誘導体及びその応用 Expired - Fee Related JP5592490B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200910192063.0 2009-09-04
CN2009101920630A CN101638435B (zh) 2009-09-04 2009-09-04 一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用
PCT/CN2010/073124 WO2011026351A1 (zh) 2009-09-04 2010-05-24 一种蓝藻病毒蛋白n 突变体、其修饰衍生物及应用

Publications (2)

Publication Number Publication Date
JP2013503609A JP2013503609A (ja) 2013-02-04
JP5592490B2 true JP5592490B2 (ja) 2014-09-17

Family

ID=41613629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012527184A Expired - Fee Related JP5592490B2 (ja) 2009-09-04 2010-05-24 シアノビリン−ｎ変異体、その修飾誘導体及びその応用

Country Status (4)

Country Link
JP (1) JP5592490B2 (enrdf_load_stackoverflow)
CN (1) CN101638435B (enrdf_load_stackoverflow)
IN (1) IN2012DN02837A (enrdf_load_stackoverflow)
WO (1) WO2011026351A1 (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101638435B (zh) * 2009-09-04 2011-11-16 暨南大学 一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用
MX370715B (es) * 2013-02-05 2019-12-20 Agricultural Tech Res Inst Vacuna de subunidades anti-mycoplasma spp.
CN110903363A (zh) * 2019-11-26 2020-03-24 中国药科大学 一种蓝藻抗病毒蛋白n的制备方法及应用
CN111494604B (zh) * 2020-05-11 2022-05-06 中国药科大学 蓝藻抗病毒蛋白n在制备抗炎药物中的应用
US20230355708A1 (en) * 2020-09-29 2023-11-09 Drexel University Compositions for inhibiting viral entry and methods using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843882A (en) * 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
EP1488804A4 (en) * 2002-03-22 2006-10-25 Bipha Corp IMMUNOGLOBULIN / HYDROPHILIC PEPTIDE COMPLEXES
WO2004056852A2 (en) * 2002-12-19 2004-07-08 Nektar Therapeutics Al, Corp. Cyanovirin variant-polymer conjugates
CN101705241B (zh) * 2008-09-28 2012-06-06 暨南大学 重组蓝藻抗病毒蛋白的制备方法及应用
CN101638435B (zh) * 2009-09-04 2011-11-16 暨南大学 一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用

Also Published As

Publication number Publication date
JP2013503609A (ja) 2013-02-04
CN101638435A (zh) 2010-02-03
CN101638435B (zh) 2011-11-16
IN2012DN02837A (enrdf_load_stackoverflow) 2015-07-24
WO2011026351A1 (zh) 2011-03-10

Similar Documents

Publication Publication Date Title
JP5592490B2 (ja) シアノビリン−ｎ変異体、その修飾誘導体及びその応用
JP2008507298A5 (enrdf_load_stackoverflow)
CN108864292B (zh) 一种干扰素重组融合蛋白及其应用
CN101432428A (zh) 重组人干扰素样蛋白
CN117285613A (zh) 结合kras-g12v突变抗原的t细胞受体或其抗原结合片段和应用
CN103755810B (zh) 一种长效hiv‐1膜融合抑制剂
CN111269899B (zh) 具有催化活性的人源尿酸氧化酶及其应用
CN1488641A (zh) 抑制sars冠状病毒的多肽药物及其衍生物和其应用
US10874745B2 (en) Antimicrobial peptides and methods of treating gram-negative pathogens: polar and non-polar face analogs
CN101265291A (zh) 一种重组猪源抗菌肽pg4及其生物合成方法与应用
Morimoto et al. Anti-influenza virus activity of high-mannose binding lectins derived from genus Pseudomonas
JP2011521648A5 (enrdf_load_stackoverflow)
CA2348308A1 (en) Rantes-derived peptides with anti-hiv activity
CN113185585B (zh) Tom70蛋白特异性结合多肽及其应用
CN1980952A (zh) 多聚化hiv融合抑制物
CN104277113B (zh) 抑制hiv感染的二价多肽
CN110551179B (zh) 一种经修饰的抗hiv多肽及其制备方法和用途
JP2023522423A (ja) インターフェロンアルファ２バリアント及びその使用
CN1752211B (zh) 用于治疗获得性免疫缺陷综合征的重组靶向融合蛋白
CN115385998B (zh) 稳定的iii型干扰素蛋白及其融合蛋白
CN103724404B (zh) 抑制hiv病毒与宿主细胞融合的非对映体多肽及其用途
US20200071357A1 (en) Antimicrobial peptides
Kajiwara et al. Bioorganic synthesis of a recombinant HIV-1 fusion inhibitor, SC35EK, with an N-terminal pyroglutamate capping group
CN104710523A (zh) 对铜绿假单胞菌具有抗菌性能的Magainin肽修饰物及其制备方法
CN1448405A (zh) 人截短型重组可溶性trail－170蛋白及其在制备肿瘤治疗药物中的应用

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131008

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140729

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140731

R150 Certificate of patent or registration of utility model

Ref document number: 5592490

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees